% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Vglein:162760,
      author       = {Vöglein, Jonathan and Kostova, Irena and Arzberger, Thomas
                      and Noachtar, Soheyl and Dieterich, Marianne and Herms,
                      Jochen and Schmitz, Peer and Ruf, Viktoria and Windl, Otto
                      and Roeber, Sigrun and Simons, Mikael and Höglinger,
                      Günter and Danek, Adrian and Giese, Armin and Levin,
                      Johannes},
      title        = {{S}eizure prevalence in neurodegenerative diseases-a study
                      of autopsy proven cases.},
      journal      = {European journal of neurology},
      volume       = {29},
      number       = {1},
      issn         = {1351-5101},
      address      = {Oxford},
      publisher    = {Blackwell Science},
      reportid     = {DZNE-2021-01416},
      pages        = {12-18},
      year         = {2022},
      note         = {ISSN 1468-1331 not unique: **2 hits**. (CC BY-NC)},
      abstract     = {Knowledge about the seizure prevalence in the whole
                      symptomatic course, from disease onset to death, in
                      neurodegenerative diseases (ND) is lacking. Therefore, the
                      aim was to investigate seizure prevalence and associated
                      clinical implications in neuropathologically diagnosed
                      ND.Clinical records of cases from the Neurobiobank Munich,
                      Germany, were analyzed. Neuropathological diagnoses of the
                      assessed cases included Alzheimer disease (AD), corticobasal
                      degeneration (CBD), frontotemporal lobar degeneration
                      (FTLD), Lewy body disease (LBD), multiple system atrophy
                      (MSA) and progressive supranuclear palsy (PSP). Seizure
                      prevalence during the whole symptomatic disease phase was
                      assessed and compared amongst ND. Associations between first
                      clinical symptom and seizure prevalence and between seizures
                      and disease duration were examined.In all, 454 patients with
                      neuropathologically diagnosed ND and with available and
                      meaningful clinical records were investigated (AD,
                      n = 144; LBD, n = 103; PSP, n = 93; FTLD, n = 53;
                      MSA, n = 36; CBD, n = 25). Seizure prevalence was
                      $31.3\%$ for AD, $20.0\%$ for CBD, $12.6\%$ for LBD,
                      $11.3\%$ for FTLD, $8.3\%$ for MSA and $7.5\%$ for PSP.
                      Seizure prevalence was significantly higher in AD compared
                      to FTLD (p = 0.005), LBD (p = 0.001), MSA (p = 0.005)
                      and PSP (p < 0.001). No other significant differences
                      regarding seizure prevalence were found between the studied
                      ND. Cognitive first symptoms in ND were associated with an
                      increased seizure prevalence $(21.1\%$ vs. $11.0\%$ in
                      patients without cognitive first symptoms) and motor first
                      symptoms with a decreased seizure prevalence $(10.3\%$ vs.
                      $20.5\%$ in patients without motor first symptoms). Seizures
                      were associated with a longer disease duration in MSA (12.3
                      vs. 7.0 years in patients without seizures;
                      p = 0.017).Seizures are a clinically relevant comorbidity
                      in ND, particularly in AD. Knowledge of the first clinical
                      symptom in ND may allow for estimation of seizure risk.},
      keywords     = {Autopsy / Humans / Multiple System Atrophy: epidemiology /
                      Multiple System Atrophy: pathology / Prevalence / Seizures:
                      epidemiology / Supranuclear Palsy, Progressive: diagnosis /
                      Supranuclear Palsy, Progressive: epidemiology / Alzheimer
                      disease (Other) / epilepsy (Other) / neurodegenerative
                      diseases (Other) / seizure prevalence (Other) / seizures
                      (Other)},
      cin          = {Clinical Dementia Research München / AG Höglinger 1 /
                      Neuropathology / Brainbank / AG Höglinger 2 / AG Herms / AG
                      Neumann / AG Simons},
      ddc          = {610},
      cid          = {I:(DE-2719)1111016 / I:(DE-2719)1110002 /
                      I:(DE-2719)1140013 / I:(DE-2719)1111015 / I:(DE-2719)1110001
                      / I:(DE-2719)1210003 / I:(DE-2719)1110008},
      pnm          = {353 - Clinical and Health Care Research (POF4-353) / 352 -
                      Disease Mechanisms (POF4-352) / 351 - Brain Function
                      (POF4-351)},
      pid          = {G:(DE-HGF)POF4-353 / G:(DE-HGF)POF4-352 /
                      G:(DE-HGF)POF4-351},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:34472165},
      doi          = {10.1111/ene.15089},
      url          = {https://pub.dzne.de/record/162760},
}